Summary
Quelamycin is triferric doxorubicin, a metallic derivative of adriamycin which, in experimental studies, has been found to have a better therapeutic index than adriamycin and no cardiotoxicity. In Spain, phase I clinical trials carried out in 96 patients with advanced cancer have shown that the drug has low toxicity and considerable antitumor activity, while it is not cardiotoxic, even at cumulative doses of nearly 3 g.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Brugarolas A, Gratia Marco M, Garcia Miralles MT, Ribas A, Valle M, Izarguzaga I (to be published) Prevention of long term iron associated toxicity of quelamycin by deferoxamine. Cancer Treat Rep
Brugarolas A, Lacave AJ, Gratia Marco M, Buesa JM, Cortes H, Gosalvez M (to be published) Quelamycin. Cancer Chemother Rev
Brugarolas A, Pachon N, Perez-Llanderal JA, Lacave AJ, Buesa JM, Gratia Marco M (1978) Phase I clinical trial of quelamycin. Cancer Treat Rep 62:1527–1534
Brugarolas A, Perez Llanderal JA, Garcia Miralles MT, Lacave AJ, Gratia Marco M, Izquierdo JM, Rodriguez Lloviran AL, Ribas A (1979) Iron toxicity studies of quelamycin. Cancer Treat Rep 63:909–913
Cortés-Funes H, Gosálvez M, Moyano A, Manas A, Mendiola C (1979) Early trial clinical with quelamycin. Cancer Treat Rep 63:903–908
Cortés-Funes H, Vicente J, Baena L, Otero J, Gosálvez M (1978) Preliminary evaluation of a phase I clinical study of quelamycin. Eur J Cancer 14:1359–1361
Gosálvez M (1976) Triferric adriamycin, a possible noncardiotoxic derivative with antitumor activity equal to adriamycin. In: Proceedings of the tenth International Congress of Biochemistry. Edited by the International Union of Biochemistry. Published by Brönners Druckerei Breidenstein KG. Hamburg, July 25, 1976
Gosálvez M, Blanco MF (1975) Inhibition of Na-K ATPase by the antitumor antibiotic adriamycin. In: Proceedings of the 5th International Biophysic Congress. Edited by the International Union for pure and applied Biophysics. Printed in Denmark by Villedsen and Christensen. Copenhagen, August, 1975
Gosálvez M, Blanco MF (1978) Requirements for the inhibition of sodium and potassium ion transporting adenosine triphosphatase by adriamycin. Biochem Soc Trans 6:945–947
Gosálvez M, Blanco MF, Vivero C, Vallés F (1978) Quelamycin, a new derivative of adriamycin with several possible therapeutic advantages. Eur J Cancer 14:1185–1190
Gosálvez M, Rossum GDV van, Blanco MF (1979) Inhibition of sodium-potassium activated adenosine-5-triphosphatase and ion transport by adriamycin. Cancer Res 39:257–261
Rossum GDV van, Gosálvez M (1976) Inhibition of ion transport by the antitumor antibioticadriamycin. Fed Proc 35: 3201
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1980 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Cortés-Funes, H., Brugarolas, A., Gosálvez, M. (1980). Quelamycin: A Summary of Phase I Clinical Trials. In: Mathé, G., Muggia, F.M. (eds) Cancer Chemo- and Immunopharmacology. Recent Results in Cancer Research, vol 74. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-81488-4_25
Download citation
DOI: https://doi.org/10.1007/978-3-642-81488-4_25
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-81490-7
Online ISBN: 978-3-642-81488-4
eBook Packages: Springer Book Archive